Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products and services that enable fundamental research, discovery, and pre-clinical testing for drug development. The company is headquartered in Holliston, Massachusetts and currently employs 436 full-time employees. The company went IPO on 2013-10-21. The company has organized its product line activities into two product families, cellular and molecular technology (CMT) and Preclinical. Its CMT product family is composed of products supporting research related to molecular, cellular organ and organoid technologies, with additional application in the field of bio-production of pharmaceuticals and therapeutics. Its preclinical product family includes four business lines that support the preclinical research and testing phase for drug development, and in particular testing related to data collection and analysis for safety and regulatory compliance. Its brands include Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs and others.